CRIS Current Research Information System

FREGA, GIORGIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.886
AS - Asia 2.550
EU - Europa 1.959
AF - Africa 222
SA - Sud America 122
Continente sconosciuto - Info sul continente non disponibili 2
OC - Oceania 1
Totale 7.742
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.849
SG - Singapore 831
CN - Cina 723
IT - Italia 506
VN - Vietnam 464
GB - Regno Unito 301
SE - Svezia 284
DE - Germania 213
HK - Hong Kong 183
KR - Corea 121
IN - India 114
IE - Irlanda 109
CH - Svizzera 101
NL - Olanda 94
BR - Brasile 85
RU - Federazione Russa 75
CI - Costa d'Avorio 69
FR - Francia 68
SC - Seychelles 58
FI - Finlandia 53
TG - Togo 31
NG - Nigeria 29
CA - Canada 24
BG - Bulgaria 22
ID - Indonesia 21
JO - Giordania 21
ZA - Sudafrica 21
AT - Austria 19
UA - Ucraina 19
GR - Grecia 18
EE - Estonia 17
PL - Polonia 15
BE - Belgio 13
AR - Argentina 12
JP - Giappone 11
TR - Turchia 11
ES - Italia 8
MX - Messico 8
PS - Palestinian Territory 8
CL - Cile 7
EC - Ecuador 7
IQ - Iraq 7
IR - Iran 6
PH - Filippine 6
BD - Bangladesh 5
CO - Colombia 5
PT - Portogallo 5
TN - Tunisia 5
NI - Nicaragua 4
RO - Romania 4
DK - Danimarca 3
LT - Lituania 3
MY - Malesia 3
PK - Pakistan 3
PY - Paraguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
EG - Egitto 2
HU - Ungheria 2
KZ - Kazakistan 2
MA - Marocco 2
SI - Slovenia 2
TW - Taiwan 2
UG - Uganda 2
UZ - Uzbekistan 2
VE - Venezuela 2
AE - Emirati Arabi Uniti 1
CG - Congo 1
CM - Camerun 1
CZ - Repubblica Ceca 1
GI - Gibilterra 1
HR - Croazia 1
HT - Haiti 1
IL - Israele 1
LB - Libano 1
LK - Sri Lanka 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PE - Perù 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
SN - Senegal 1
TH - Thailandia 1
Totale 7.742
Salva come PNG Salva come JPEG
Città #
Singapore 578
Dallas 404
Ashburn 332
Chandler 285
Hefei 285
Southend 249
Dong Ket 188
Hong Kong 183
Fairfield 182
Santa Clara 126
Seoul 112
Dublin 109
Houston 107
Princeton 97
Bern 94
Bologna 89
Beijing 86
Ho Chi Minh City 80
Wilmington 80
Woodbridge 80
Seattle 72
Abidjan 69
Boardman 64
Cambridge 55
Ann Arbor 53
Hanoi 50
Rome 46
Los Angeles 45
Helsinki 42
New York 42
Frankfurt am Main 33
Lomé 31
Berlin 30
Milan 30
Nanjing 29
Bengaluru 27
Redondo Beach 26
Turin 26
Westminster 25
Redmond 23
Sofia 22
Amman 21
San Diego 19
Abeokuta 18
Buffalo 18
Florence 18
Jakarta 18
London 16
Padova 14
São Paulo 14
Tongling 14
Brussels 12
Medford 12
Munich 12
Ravenna 11
Tokyo 11
Jinan 10
Chicago 9
Toronto 9
Warsaw 9
Groningen 8
Guangzhou 8
Halhul 8
Olalla 8
Phoenix 8
Saint Petersburg 8
Yubileyny 8
Zhengzhou 8
Bremen 7
Haiphong 7
Lappeenranta 7
Shanghai 7
Torino 7
Vienna 7
Chennai 6
Da Nang 6
Forlì 6
Hebei 6
Istanbul 6
Lauterbourg 6
Mexico City 6
Montreal 6
Ninh Bình 6
Nuremberg 6
Orem 6
Poplar 6
Portsmouth 6
Shenyang 6
Tianjin 6
Bühl 5
Changsha 5
Denver 5
Falkenstein 5
Fremont 5
Hyderabad 5
Jacksonville 5
Nanchang 5
Ottawa 5
Quận Bình Thạnh 5
Redwood City 5
Totale 5.102
Salva come PNG Salva come JPEG
Nome #
Follow-up del cancro del pancreas esocrino 400
Adjuvant treatment in biliary tract cancer 315
D32Left versus right side primary tumor: the correlation with clinical outcome of patients with resected stage II and III colorectal cancer 273
SUSTAINED COMPLETE RESPONSE OF ADVANCED HEPATOCELLULAR CARCINOMA WITH METRONOMIC CAPECITABINE: A REPORT OF THREE CASES 262
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone 256
Brain Metastases from Biliary Tract Cancer: A Monocentric Retrospective Analysis of 450 Patients 217
Antitumoral efficacy of the protease inhibitor gabexate mesilate in colon cancer cells harbouring KRAS, BRAF and PIK3CA mutations 212
Antitumoral Efficacy of Two Turmeric Extracts According to Different Extraction Methods in Hepatocellular Carcinoma Cell Lines 204
Membrane human equilibrative nucleoside transporter 1 is associated with a high proliferation rate and worse survival in resected intrahepatic cholangiocarcinoma patients not receiving adjuvant treatments 200
Membrane localization of human equilibrative nucleoside transporter 1 in tumor cells may predict response to adjuvant gemcitabine in resected cholangiocarcinoma patients 194
Asbestos exposure as an additional risk factor for small duct intrahepatic cholangiocarcinoma: a pilot study 191
Metronomic capecitabine vs. best supportive care in Child-Pugh B hepatocellular carcinoma: A proof of concept 184
How to choose between percutaneous transhepatic and endoscopic biliary drainage in malignant obstructive jaundice: An updated systematic review and meta-analysis 181
TERC and c-MYC COPY number gain in intraductal papillary mucinous neoplasms (IPMNs): promising biomarkers of progression to malignancy 178
Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience 174
The (Eternal) Debate on Microwave Ablation Versus Radiofrequency Ablation in BCLC-A Hepatocellular Carcinoma 174
Second-line treatment in advanced biliary tract cancer: Today and tomorrow 172
Bone metastases in biliary cancers: A multicenter retrospective survey 171
In Reply 169
INTRAHEPATIC CHOLANGIOCARCINOMA DEVELOPMENT IN A PATIENT WITH A NOVEL BAP1 GERMLINE MUTATION AND LOW EXPOSURE TO ASBESTOS 169
Anti-EGFR monoclonal antibodies in advanced biliary tract cancer: A systematic review and meta-analysis 168
TERC AND MYC COPY NUMBER GAIN AS POWERFUL GENETIC MARKERS FOR INTRADUCTAL PAPILLARY NEOPLASMS OF THE PANCREAS 161
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumour Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 156
Postsorafenib systemic treatments for hepatocellular carcinoma: Questions and opportunities after the regorafenib trial 153
The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation 152
Challenges in Repurposing Drugs in COVID-19 Pandemic. Debating on Potential New Refinements 150
Bone Turnover Marker (BTM) Changes after Denosumab in Giant Cell Tumors of Bone (GCTB): A Phase II Trial Correlative Study 146
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience 142
Chemotherapy in Patients with Advanced Cholangiocarcinoma 141
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) to predict better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 136
The Potential Role of Adjuvant Chemoradiotherapy in Patients with Microscopically Positive (R1) Surgical Margins after Resection of Cholangiocarcinoma 131
Immunotherapy in Pancreatic Cancer: Why Do We Keep Failing? A Focus on Tumor Immune Microenvironment, Predictive Biomarkers and Treatment Outcomes 130
Dual immune checkpoint blockade in hepatocellular carcinoma: where do we stand? 129
Clinical safety and efficacy of adjuvant chemotherapy in radically resected cholangiocarcinoma patients. 128
Hacking pancreatic cancer: Present and future of personalized medicine 118
Experimental HER2- targeted therapies for biliary tract cancer 109
BAP1 in solid tumors 106
Plasma membrane localization of human equilibrative nucleoside transporter 1 (hENT-1) predicts better outcome of adjuvant gemcitabine in cholangiocarcinoma (CC) patients. 105
NTRK rearranged sarcoma of the bone. Role for larotrectinib in the neoadjuvant setting of an ultra-rare tumor: a case report 98
The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma 97
Molecular features and targeted therapies in extrahepatic cholangiocarcinoma: Promises and failures 96
Clinical insights and prognostic factors from an advanced biliary tract cancer case series: a real-world analysis 94
Nivolumab: an investigational agent for the treatment of biliary tract cancer 86
Microbiota: Overview and implication in immunotherapy-based cancer treatments 83
Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges 83
Hypothesis on the possible relevance of the immunogenic cell death in the treatment of gestational trophoblastic neoplasms 76
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: An unassessed issue 73
The Human Microbiomes in Pancreatic Cancer: Towards Evidence-Based Manipulation Strategies? 67
FGFR inhibitors in elderly patients with advanced biliary tract cancer: an unsolved issue 66
Second-line FOLFOX chemotherapy for advanced biliary tract cancer 56
The human microbiomes in pancreatic cancer: Towards evidence-based manipulation strategies? 53
A reduction in tumor volume exceeding 65% predicts a good histological response to neoadjuvant chemotherapy in patients with Ewing sarcoma 46
Trial Watch: experimental TLR7/TLR8 agonists for oncological indications 38
Histological and imaging features of myoepithelial carcinoma of the bone and soft tissue 35
Case Report: Long lasting response with TKI for combined hepatocellular-cholangiocarcinoma 27
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue 23
Totale 7.954
Salva come PNG Salva come JPEG
Categoria #
all - tutte 23.473
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.473
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021425 0 0 0 0 0 22 26 39 43 22 19 254
2021/2022920 57 29 35 68 61 33 22 54 133 85 198 145
2022/20231.265 122 169 60 133 96 96 36 79 197 47 84 146
2023/2024399 63 55 26 39 22 65 18 29 3 28 31 20
2024/20251.580 92 208 146 109 170 62 93 82 41 117 128 332
2025/20262.330 406 501 653 319 366 85 0 0 0 0 0 0
Totale 7.954